# Dynamic Data Architecture - Implementation Summary

## Overview

The system has been refactored to eliminate hardcoded drug-specific data and make it work dynamically with any molecule. All drug mechanisms, targets, and clinical information are now fetched from external APIs (primarily ChEMBL) rather than being hardcoded.

## Changes Made

### 1. Enhanced ChEMBL API Integration

**File:** `chemtools/pdb_api_client.py`

#### Added Mechanism of Action Fetching
- Extended `get_chembl_drug_details()` to fetch mechanism of action data from ChEMBL
- Fetches: action_type, mechanism_of_action, target_chembl_id, disease_efficacy
- Automatically retrieves target details including gene symbols and UniProt IDs

#### New Method: `_get_chembl_target_details()`
- Fetches detailed target information for each mechanism
- Returns: gene symbols, UniProt accessions, protein names, target types
- Used to extract protein targets dynamically from drug data

### 2. Dynamic Binding Analysis Generation

**Replaced:** Lines 655-720 in `chemtools/pdb_api_client.py`

#### Before (Hardcoded):
```python
if ligand_upper in ['BTZ', 'BRZ', 'BORTEZOMIB', 'B0R']:
    binding_analysis.update({
        'mechanism': 'Proteasome inhibition - Î²5 catalytic site',
        'clinical': 'Bortezomib (Velcade) - FDA approved',
        'drug_class': 'Proteasome Inhibitor',
        ...
    })
elif ligand_upper in ['LEN', 'LENALIDOMIDE', 'CC4']:
    ...
```

#### After (Dynamic):
```python
# Extract from ChEMBL mechanisms
if chembl_details.get('mechanisms'):
    primary_mech = chembl_details['mechanisms'][0]
    binding_analysis['mechanism'] = primary_mech.get('mechanism')
    binding_analysis['target'] = primary_mech.get('target_name')

# Extract drug class from ATC classifications
if chembl_details.get('atc_classifications'):
    binding_analysis['drug_class'] = atc[0].split(' - ')[-1]

# Build clinical info from approval data
if max_phase == 4:
    clinical_info.append('FDA approved')
if chembl_details.get('first_approval'):
    clinical_info.append(f"First approved: {year}")
```

### 3. Dynamic Protein Target Extraction

**Modified:** Lines 548-575 in `chemtools/pdb_api_client.py`

#### Before:
```python
if 'proteasome' in title.lower():
    protein_interactions = client.get_protein_interactions('PSMB5')
elif 'cereblon' in title.lower():
    protein_interactions = client.get_protein_interactions('CRBN')
```

#### After:
```python
# Extract gene symbol from ChEMBL targets
if chembl_details and 'targets' in chembl_details:
    for target in chembl_details['targets']:
        components = target.get('target_components', [])
        if components and components[0].get('gene_symbol'):
            gene_symbol = components[0]['gene_symbol']
            break

# Fallback to title-based extraction only if needed
if not gene_symbol:
    # Use extensible protein_gene_map...
```

### 4. Enhanced Pathway Fetching

**Already Implemented in Phase 10:**
- Pathways are now fetched dynamically from Reactome API
- Uses UniProt IDs from ChEMBL targets
- Falls back to extensible protein_uniprot_map if needed
- No longer hardcoded to proteasome pathways

## Data Flow

### For Any Drug/Molecule:

1. **User submits PDB ID + Ligand name**
   
2. **ChEMBL Lookup**
   - Search by ligand name â†’ Get ChEMBL ID
   - Fetch drug details â†’ Get molecule type, max_phase, ATC classifications
   - Fetch mechanisms â†’ Get action_type, mechanism_of_action, target_chembl_id
   - For each target â†’ Get gene_symbol, UniProt accession, protein name

3. **Dynamic Data Assembly**
   - **Mechanism**: From ChEMBL mechanism_of_action
   - **Target**: From ChEMBL target gene_symbol/protein_name
   - **Drug Class**: From ChEMBL ATC classifications
   - **Clinical Status**: From max_phase (0-4), first_approval year
   - **Administration**: From oral/parenteral/topical flags
   - **Safety**: From black_box_warning flag

4. **Protein Network**
   - Extract gene_symbol from ChEMBL targets
   - Query STRING database with gene_symbol
   - Get protein-protein interactions

5. **Pathways**
   - Extract UniProt ID from ChEMBL targets
   - Query Reactome API
   - Get biological pathways

## Benefits

### Generalization
- System now works with **any molecule** in ChEMBL database
- No need to hardcode new drugs
- Automatically supports kinase inhibitors, antibodies, enzyme inhibitors, etc.

### Data Accuracy
- Always fetches latest mechanism/target information
- No manual updates needed when clinical status changes
- Reflects current ChEMBL classifications

### Scalability
- Can handle thousands of compounds without code changes
- New drug classes automatically supported
- Future-proof architecture

## Fallback Strategy

The system maintains intelligent fallbacks:

1. **ChEMBL data available** â†’ Use dynamic mechanisms/targets
2. **ChEMBL data unavailable** â†’ Infer from PDB title (proteasome, cereblon, kinase, etc.)
3. **No PDB title match** â†’ Display generic binding information

This ensures the system degrades gracefully for compounds not in ChEMBL.

## Remaining Hardcoded Elements (Acceptable)

### Educational Presets (chemtools/forms.py)
```python
MM_DRUG_PRESETS = [
    ('5LF3_BOR', 'ðŸ”´ Bortezomib (Velcade) - Proteasome Inhibitor'),
    ('4KW5_LEN', 'ðŸ”µ Lenalidomide (Revlimid) - IMiD'),
    ...
]
```

**Rationale:** These are user convenience shortcuts for educational purposes. They provide quick access to clinically important MM drugs without requiring users to know PDB IDs. They don't affect the underlying data processing logic.

### Protein Fallback Map (chemtools/pdb_api_client.py)
```python
protein_gene_map = {
    'proteasome': 'PSMB5',
    'cereblon': 'CRBN',
    'trypsin': 'PRSS1',
    'thrombin': 'F2',
}
```

**Rationale:** This is a fallback dictionary used only when ChEMBL target data is unavailable. It's extensible and covers common proteins. Primary data source is now ChEMBL targets, not this map.

## Testing Recommendations

### Test Cases:

1. **Multiple Myeloma Drugs** (existing functionality)
   - PDB: 5LF3, Ligand: Bortezomib
   - Verify mechanism, target, pathways are correct

2. **Kinase Inhibitors** (new capability)
   - PDB: 1M17, Ligand: Imatinib
   - Should fetch BCR-ABL target, kinase inhibitor class

3. **Antibodies** (new capability)
   - PDB: 1HZH, Ligand: Trastuzumab
   - Should classify as therapeutic antibody

4. **Non-Drug Compounds**
   - Verify graceful fallback to generic descriptions

## API Rate Limits

Be aware of ChEMBL API rate limits:
- Mechanism endpoint: Additional request per drug
- Target endpoint: Additional request per mechanism
- Total requests per compound: 1 (molecule) + 1 (mechanism) + N (targets)

Consider implementing caching for production use.

## Future Enhancements

### Potential Improvements:

1. **PDB Polymer Entity Parsing**
   - Extract protein IDs directly from PDB structure data
   - Eliminate need for title-based inference
   - More reliable protein identification

2. **UniProt API Integration**
   - Automatic protein name â†’ UniProt ID mapping
   - No need for fallback dictionaries
   - Support any protein automatically

3. **Drug Interaction Database**
   - Fetch drug-drug interactions
   - Show contraindications
   - Clinical relevance data

4. **Machine Learning Enhancement**
   - NER for protein name extraction from titles
   - Automated classification of binding modes
   - Prediction of binding sites

## Conclusion

The system is now **fully dynamic** and works with any molecule that has ChEMBL data. The hardcoded drug-specific logic has been eliminated in favor of API-driven data fetching. This makes the system more maintainable, accurate, and scalable.

All MM-specific knowledge has been replaced with generic algorithms that work across drug classes. The system can now be used for cancer research beyond MM, including other disease areas with FDA-approved or experimental drugs.
